广告
加载中

ECM 线粒体抗衰 气候护肤:华熙的新故事能“救火”吗?

亿邦动力 2026-05-18 12:28
亿邦动力 2026/05/18 12:28

邦小白快读

EN
全文速览

本文核心内容是国产护肤龙头华熙生物当前陷入护肤业务增长困境,正推出新概念新品寻找新增长曲线,整理核心干货如下:

1. 华熙最新发布的新品及核心护肤方向:共有三大核心关键词,分别是润百颜白纱布4.0的ECM级修护,夸迪新品眼霜功效对标热玛吉,新品牌润兰馨主打气候定制护肤。

2. 当前护肤行业流行新“护肤故事”方向:除了新成分,现在更多品牌会从护肤路径、护肤理念推新概念,常见的有早C晚A这类新流程、分区护肤/按季节护肤新理念、新透皮技术、新皮肤问题解决路径等。

3. 当前行业竞争新趋势:国内外多个头部美妆品牌都已经布局ECM相关赛道,“让护肤品效果媲美医美”是行业共同押注的新方向。

本文梳理了华熙生物的战略调整和当前护肤行业的发展态势,能给品牌商提供多方面干货参考:

1. 行业消费与研发趋势:化妆品行业需要持续更新科研故事来吸引消费者,头部品牌已经开始摆脱对单一原料的依赖,“科技护肤”“护肤品功效对标医美”是当前热门消费方向,研发热点集中在ECM修护、线粒体抗衰、定制化护肤领域,作用路径创新比单一新成分更受关注。

2. 竞争格局参考:目前国内外头部品牌包括丸美、福瑞达、上海家化、资生堂、雅诗兰黛都已密集布局ECM赛道,赛道竞争已经十分激烈。

3. 企业调整参考:华熙在核心业务营收下滑时,通过缩减销售费用“截流”稳住归母净利润的做法,为陷入增长瓶颈的品牌提供了调整思路。

本文梳理了护肤行业的新变动和竞争格局,能给护肤类卖家提供机会、风险层面的干货参考:

1. 新增长机会提示:当前ECM科技护肤、线粒体抗衰、功效对标医美的护肤品、气候定制护肤都是行业新蓝海,消费者对新护肤概念接受度高,存在新的流量和增长机会,卖家可以围绕这些方向选品布局。

2. 风险提示:目前国内外头部品牌已经密集布局ECM赛道,福瑞达、上海家化、敷尔佳等都推出了高功效对标医美的新品,赛道竞争已经拉开,中小卖家入场需要打造差异化优势才能突围。

3. 经营调整参考:当原有核心品类增长见顶时,需要及时推出新品牌、打造新概念开辟新增长曲线,营收下滑阶段可通过缩减销售费用降本增效,稳住利润水平。

本文介绍了当前护肤终端的需求变化和头部企业的转型方向,能给护肤类工厂提供多方面干货参考:

1. 产品生产与设计需求变化:当前终端品牌的研发方向已经从单一原料概念转向作用路径创新,ECM修护、线粒体抗衰、气候定制配方是品牌方的主流新需求,工厂可以提前布局相关配方、工艺研发,更好适配品牌的新需求。

2. 商业机会:越来越多品牌布局功效对标医美的护肤品,行业对高端透皮技术、高纯度有效成分的量产需求大幅提升,工厂可以围绕这些方向开发产能,对接品牌新增订单需求。

3. 转型启示:原有围绕玻尿酸单一概念布局的产能已经出现增长瓶颈,工厂需要跟随终端消费和品牌需求变化,推进技术升级,匹配品牌新科研故事的需求,才能维持稳定订单。

本文总结了当前护肤行业的发展趋势和品牌端的核心痛点,能给护肤行业相关服务商提供明确的方向参考:

1. 行业发展趋势:护肤行业已经从原来的原料红利竞争转向科研路径、功效叙事竞争,“功效对标医美”“科技护肤”“定制化护肤”是未来行业的主流发展方向,赛道增长空间大。

2. 客户核心痛点:很多原本依赖玻尿酸单一原料红利的品牌,现在都面临核心业务下滑、增长见顶的困境,急需新的科研故事和产品概念完成品牌升级,摆脱增长瓶颈。

3. 解决方案方向:服务商可以围绕ECM技术、线粒体抗衰技术、定制化护肤方案,开发相关的营销内容输出、技术支持、供应链对接等服务,帮助品牌完成转型升级,满足品牌现阶段的需求。

本文梳理了护肤品牌现阶段的转型需求和行业竞争现状,对美妆平台的招商、运营和风险规避都有参考价值:

1. 品牌端对平台的核心需求:当前大量传统护肤品牌都在推进转型升级,推出新品牌、布局新赛道,需要平台提供新流量扶持、专属营销场景,帮助新概念产品快速触达目标消费者。

2. 平台招商与运营方向:平台可以重点引入布局ECM科技护肤、线粒体抗衰、气候定制护肤赛道的新品牌和新品,这类概念是当前行业热点,更容易撬动品类增长,也可以围绕新护肤概念打造专属营销活动,拉动销售增长。

3. 风向规避:当前护肤赛道概念创新快,不少品牌都在宣传功效对标医美,平台需要引导商家规范功效宣传,避免夸大宣传引发的监管风险。

本文记录了国产玻尿酸龙头华熙生物的转型过程,揭露了护肤产业的新动向与新问题,对产业研究有较高的参考价值:

1. 产业新动向:国内护肤产业已经从原料红利时代进入概念创新、科研叙事的新阶段,头部企业纷纷摆脱对单一核心原料的依赖,转向作用路径创新,ECM修护、线粒体抗衰、定制护肤成为新的热门赛道,护肤品功效对标医美成为新的竞争方向。

2. 产业新问题:头部企业过度依赖单一原料红利会陷入增长瓶颈,华熙当前出现增利不增收、核心护肤业务连年下滑的问题,靠缩减销售费用维持利润的模式不具备可持续性,传统增长逻辑已经失效。

3. 商业模式研究样本:华熙通过升级老品牌定位、推出新品牌,围绕新科研方向打造新增长曲线的转型模式,为原料龙头企业向下游品牌端转型提供了研究样本,也为研究国内美妆产业竞争格局提供了最新案例。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article focuses on Bloomage Biotech, China’s leading hyaluronic acid player, which is currently facing growth headwinds in its skincare business and launching new concept products to find a fresh growth curve. The key takeaways are as follows:

1. Bloomage’s latest new products and core skincare focus: Three key themes are defined. Biohyalux’s White Mesh 4.0 focuses on ECM-level skin repair; QuadHA’s new eye cream positions its efficacy as comparable to Thermage; and the new brand Runlanxin specializes in climate-customized skincare.

2. Current popular "new skincare narratives" in the industry: Beyond new ingredients, more brands are rolling out new concepts based on skincare routines and philosophies. Common examples include new routines like "Morning Vitamin C, Evening Retinol", new concepts such as zoning skincare and seasonal skincare, new transdermal delivery technologies, and new approaches to addressing skin concerns.

3. New industry competition trends: Multiple leading domestic and international beauty brands have already entered the ECM-related segment, and "making skincare products match the efficacy of medical aesthetic treatments" is a new direction the whole industry is betting on.

This article sorts out Bloomage Biotech’s strategic adjustments and the current development trend of the skincare industry, offering actionable takeaways for brand owners:

1. Consumer and R&D trends: The cosmetics industry needs to continuously update its science-backed narratives to attract consumers. Leading brands are moving beyond reliance on single ingredients. "Tech-forward skincare" and "efficacy matching medical aesthetics" are currently popular consumer-facing directions, with R&D focused on ECM repair, mitochondrial anti-aging, and customized skincare. Innovation in mechanisms of action receives more attention than single new ingredients.

2. Competitive landscape reference: Leading domestic and international brands including Marubi, Freda, Jahwa, Shiseido and Estée Lauder have already made heavy investments in the ECM segment, making competition in this space already very intense.

3. Reference for corporate restructuring: When its core business revenue declined, Bloomage stabilized net profit attributable to shareholders by cutting selling expenses. This approach provides an adjustment blueprint for brands stuck in growth bottlenecks.

This article summarizes recent shifts and the competitive landscape of the skincare industry, offering insights into opportunities and risks for skincare sellers:

1. New growth opportunity alerts: ECM tech skincare, mitochondrial anti-aging, products with efficacy comparable to medical aesthetics, and climate-customized skincare are all new blue oceans in the industry. Consumers are highly receptive to these new skincare concepts, creating new traffic and growth opportunities. Sellers can build their product assortment around these directions.

2. Risk alerts: Leading domestic and international brands have already entered the ECM track en masse, with players including Freda, Jahwa and Vollya launching new high-efficacy products targeting medical aesthetic-level results. Competition in this segment is already underway, so small and medium-sized sellers need to build differentiated advantages to break through when entering the market.

3. Reference for business adjustment: When growth of original core categories plateaus, brands need to launch new brands and develop new concepts in a timely manner to open up new growth curves. During periods of declining revenue, cutting selling expenses can help cut costs, boost efficiency and stabilize profits.

This article introduces current changes in end-market skincare demand and the transformation direction of leading companies, offering key insights for skincare manufacturers:

1. Changes in product manufacturing and design demand: R&D focus of end brands has shifted from single-ingredient concepts to innovation in mechanisms of action. ECM repair, mitochondrial anti-aging and climate-customized formulations are the main new demands from brand owners. Manufacturers can conduct R&D on relevant formulations and processes in advance to better align with brands’ new needs.

2. Business opportunities: As more brands roll out skincare products with efficacy matching medical aesthetics, industry demand for mass production of advanced transdermal technologies and high-purity active ingredients has increased significantly. Manufacturers can develop production capacity around these directions to meet the new order demand from brands.

3. Transformation insights: Production capacity originally built around the single hyaluronic acid concept has hit a growth ceiling. To maintain stable order flow, manufacturers need to follow changes in end consumer demand and brand needs, push forward technological upgrades, and align with brands’ demand for new science-backed narratives.

This article summarizes current skincare industry trends and core pain points for brands, providing clear directional guidance for skincare industry service providers:

1. Industry development trends: The skincare industry has shifted from competition based on raw material dividends to competition based on scientific mechanisms and efficacy narratives. "Efficacy matching medical aesthetics", "tech-forward skincare" and "customized skincare" are the mainstream development directions for the future, with large room for growth.

2. Core customer pain points: Many brands that originally relied on the hyaluronic acid raw material dividend are now facing the dilemma of declining core business growth and plateaued growth. They urgently need new scientific narratives and product concepts to complete brand upgrading and break through growth bottlenecks.

3. Solution directions: Service providers can develop related services around ECM technology, mitochondrial anti-aging technology, and customized skincare solutions, including marketing content output, technical support, and supply chain matching, to help brands complete transformation and upgrading, and meet brands’ current-stage needs.

This article sorts out the transformation needs of skincare brands and the current status of industry competition, offering reference for beauty platforms in merchant recruitment, operations and risk mitigation:

1. Core demand from brands to platforms: A large number of traditional skincare brands are currently promoting transformation and upgrading, launching new brands and entering new tracks. They need platforms to provide new traffic support and exclusive marketing scenarios to help new concept products reach target consumers quickly.

2. Platform merchant recruitment and operation directions: Platforms can prioritize onboarding new brands and new products focused on ECM tech skincare, mitochondrial anti-aging, and climate-customized skincare. These concepts are current industry hotspots, more likely to drive category growth. Platforms can also create exclusive marketing campaigns around new skincare concepts to boost sales growth.

3. Risk mitigation: Concepts in the skincare track innovate rapidly, and many brands promote their products as matching medical aesthetic efficacy. Platforms need to guide merchants to standardize efficacy claims and avoid regulatory risks caused by over-promising.

This paper documents the transformation process of Bloomage Biotech, China’s domestic hyaluronic acid leader, and reveals new trends and problems in the skincare industry, offering high reference value for industrial research:

1. New industrial trends: China’s skincare industry has moved from the era of raw material dividends to a new stage of concept innovation and science-backed storytelling. Leading enterprises are increasingly moving away from reliance on a single core raw material and turning to innovation in mechanisms of action. ECM repair, mitochondrial anti-aging, and customized skincare have become new popular tracks, and matching medical aesthetic efficacy has become a new competitive direction.

2. New industrial problems: Over-reliance on single raw material dividends leaves leading enterprises stuck in growth bottlenecks. Bloomage is currently facing the situation of profit growth without revenue growth, with its core skincare business declining for consecutive years. Its model of maintaining profit by cutting selling expenses is not sustainable, and the traditional growth logic has failed.

3. Research sample for business models: Bloomage’s transformation model of upgrading old brand positioning, launching new brands, and building new growth curves around new scientific directions provides a research sample for leading raw material enterprises transforming into downstream brand operations, as well as an latest case study for analyzing the competitive landscape of China’s beauty industry.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】近期的CBE中国美容博览会上,华熙生物发布多款新品,其中关键词有三:一是润百颜白纱布4.0的“ECM级修护”,二是夸迪眼霜新品“功效对标热玛吉”,三是新品牌润兰馨的气候护肤理念。

这些关键词背后,是华熙在护肤侧押注的科研和科学传播方向:ECM科技、线粒体抗衰、气候护肤等。而这三个关键词都在透传出:华熙正在寻找新科研故事。

曾经,华熙在市场上的戏称是“玻尿酸三剑客”之一。在2025年与巨子的所谓商战中也可看出,华熙很忌讳“透明质酸是过时原料”的说法。但不同于医疗乃至医美,化妆品时刻需要新故事。

从使用端看,新故事可以是“泥膜+洗面奶”的新概念,或“早C晚A”的新护肤流程,或分区精准护肤、按季节护肤的新理念;从研发端看,新故事可以是某种新天然成分,或在实验室实现量产的新成分,亦或是更高效的新透皮方法,乃至类似“护肤要修护ECM”的皮肤问题解决路径。

从华熙目前的形势和对手们的急切表现来看,至少在护肤侧,华熙急需新故事“救火”。

01 增利不增收,护肤业务急需“救火”

从财报表现来看,华熙处于“增利不增收”的局面中。

皮肤科学创新转化业务连年下滑,2025年营收14.87亿元,同比下降42.11%;原料和医疗终端产品分别营收12.1亿元和13.69亿元,整体微降但稳定,却难补皮肤科学创新转化业务的空缺。

而营收的下降也主要由皮肤科学创新转化业务导致:总营收41.99亿元,对比去年减少11.72亿元,而仅皮肤科学创新转化业务一项便下降了10.82亿元。

归母净利润2.92亿元,同比增长67.59%,则主要由“截流”而非“开源”贡献:营业总成本38.26亿元,对比去年减少12.14亿元,其中仅销售费用一项便从去年的24.64亿元减少至15.15亿元,减少整整9.49亿元。

2026年Q1,情况仍未完全好转:总营收8.29亿元,同比下降23.06%;归母净利润0.65亿元,同比下降36.55%。

华熙在2026年延续了2025年的调整策略:在总营收下滑的前提下,由减少销售费用驱动营业总成本的下降,从而尽可能保证归母净利润的稳定。营业总成本7.53亿元,对比去年同期(9.44亿元)减少1.91亿元,其中销售费用2.63亿元,对比去年同期减少1.31亿元。

针对归母净利润的下降,华熙解释为公司对部分生产设备集中停产检修,合计影响利润约0.25亿元,同时政府补助有所减少,影响利润约0.09亿元。但即便完全排除这两个影响因素,其归母净利润仍同比下降约3%。

值得注意的是,在说明利润端承压原因时,华熙特意说明了“皮肤科学创新转化业务在经营层面仍在调整”。这一因素与2025年相同。

02 竞对密集布局,华熙品牌升级能否“救火”?

为了“救”护肤品业务,华熙生物正在进行战略性调整。

2025年,华熙推出新护肤品牌“润兰馨”,主张根据用户所在地的气候定制护肤方案。该品牌于4月在消博会完成全球首发,5月携新品“水漾生态系列”在CBE美博会举办发布会。

实际上,2025年起,华熙就在为旗下品牌寻找新方向。如润百颜品牌定位升级为“ECM科技护肤领导者”,夸迪定位升级为“生命科技·逆龄抗老”,核心为“以细胞级专利抗老技术CT50,调控线粒体”。

ECM,即细胞外基质,位于真皮层的细胞间质之间,由胶原蛋白、弹性纤维等成分组成复合的网络结构。有学者用“床垫”比喻ECM:如果ECM健康,则“床垫”弹性好,皮肤紧致、饱满、有弹性。

2025年Q1,华熙开始在财报中提及ECM,同年中期报告中提及,相关技术已应用于润百颜医美产品(如润百颜·玻玻、润致·缇透等)中,并提及将精准透明质酸在ECM中的作用应用于润百颜品牌。而在2025年,润百颜护肤品的品牌定位彻底升级为“ECM科技护肤领导者”。

从“讲故事”的思路来看,华熙的科学传播集中于新作用路径:润百颜主张作用于ECM以修护,夸迪则主张作用于线粒体以抗老。而从对外功效宣讲来看,华熙的方向是让护肤品效果从某种程度上替代医美。

例如,财报中提及,润百颜的护肤品“与医美产品作用的底层逻辑相同”;夸迪新品“动能支撑轻龄眼霜”,在新品发布会中将其功效对标热玛吉。

而从竞争格局看,目前丸美生物、福瑞达、上海家化都已进军ECM相关赛道。国际上,资生堂、雅诗兰黛等集团也在集中布局ECM相关研究。同时,在“用护肤品达成医美效果”方面,福瑞达、上海家化、敷尔佳等集团的新品也在迎头赶上:

福瑞达新品水光面膜,可达成30分钟即刻水光淡纹效果;上海家化旗下典萃多肽2.0奇迹瓶,其核心成分环二肽-1,作用于ECM层面,宣称效果可媲美肉毒针加胶原针;敷尔佳PDRN水光系列,核心双穿水光技术能智慧地让医美注射级别的PDRN“去到该去的地方”。

华熙生物正在用ECM、线粒体、气候护肤等新概念,试图填补玻尿酸之外的增长空白。对华熙而言,这是一场不能输的换挡赛。

亿邦持续追踪报道该情报,如想了解更多与本文相关信息,请扫码关注作者微信。

文章来源:亿邦动力

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

+1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0